このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Gilead Sciences マネジメント

マネジメント基準チェック /34

Gilead Sciences'の CEO はDan O'Dayで、 Mar2019年に任命され、の在任期間は 5.25年です。の年間総報酬は$ 22.61Mで、 7.7%給与と92.3%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.039%を直接所有しており、その価値は€ 29.36M 。経営陣と取締役会の平均在任期間はそれぞれ4.3年と6.1年です。

主要情報

Dan O'Day

最高経営責任者

US$22.6m

報酬総額

CEO給与比率	7.7%
CEO在任期間	5.3yrs
CEOの所有権	0.04%
経営陣の平均在職期間	4.3yrs
取締役会の平均在任期間	6.1yrs

経営陣の近況

Recent updates

CEO報酬分析

Gilead Sciences の収益と比較して、Dan O'Day の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	US$485m
Dec 31 2023	US$23m	US$2m	US$6b
Sep 30 2023	n/a	n/a	US$6b
Jun 30 2023	n/a	n/a	US$5b
Mar 31 2023	n/a	n/a	US$6b
Dec 31 2022	US$22m	US$2m	US$5b
Sep 30 2022	n/a	n/a	US$3b
Jun 30 2022	n/a	n/a	US$4b
Mar 31 2022	n/a	n/a	US$5b
Dec 31 2021	US$19m	US$2m	US$6b
Sep 30 2021	n/a	n/a	US$7b
Jun 30 2021	n/a	n/a	US$5b
Mar 31 2021	n/a	n/a	US$301m
Dec 31 2020	US$19m	US$2m	US$123m
Sep 30 2020	n/a	n/a	US$1b
Jun 30 2020	n/a	n/a	-US$257m
Mar 31 2020	n/a	n/a	US$5b
Dec 31 2019	US$29m	US$1m	US$5b

報酬と市場: Danの総報酬 ($USD 22.61M ) は、 German市場 ($USD 5.00M ) の同規模の企業の平均を上回っています。

報酬と収益: Danの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Dan O'Day (60 yo)

5.3yrs

在職期間

US$22,607,690

報酬

Mr. Daniel P. O'Day, also known as Dan, served as Non-Executive Non-Independent Director for Galapagos NV since October 22, 2019 until March 26, 2024. He served as Member of Supervisory Board at Galapagos...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Daniel P. O'Day	Chairman & CEO	5.3yrs	US$22.61m	0.039% $ 29.4m
Andrew Dickinson	Chief Financial Officer	4.6yrs	US$8.11m	0.011% $ 8.2m
Deborah Telman	Executive VP of Corporate Affairs	1.8yrs	US$5.27m	0.0012% $ 872.5k
Johanna Mercier	Chief Commercial Officer	4.9yrs	US$8.59m	0.0097% $ 7.2m
Merdad Parsey	Chief Medical Officer	4.6yrs	US$8.39m	0.0079% $ 5.9m
Sandra Patterson	Senior VP	1.3yrs	データなし	0.0027% $ 2.0m
Jacquie Ross	Vice President of Investor Relations	3.4yrs	データなし	データなし
Jyoti Mehra	Executive Vice President of Human Resources	4.8yrs	データなし	データなし
Linda Higgins	Senior Vice President of Research	4.3yrs	データなし	データなし
Rudolf Ertl	Senior Vice President of Commercial Operations of Australia	no data	データなし	データなし
Flavius Martin	Executive Vice President of Research	3.2yrs	データなし	データなし
William Grossman	Senior Vice President & Therapeutic Area Head of Gilead Oncology	2.9yrs	データなし	データなし

4.3yrs

平均在職期間

58yo

平均年齢

経験豊富な経営陣: GISの経営陣は経験豊富であると考えられます ( 4.3年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Daniel P. O'Day	Chairman & CEO	5.3yrs	US$22.61m	0.039% $ 29.4m
Anthony Welters	Lead Independent Director	3.7yrs	US$444.92k	0.00082% $ 611.5k
Paul Berg	Member of Scientific Advisory Board	no data	US$16.00k	データなし
Jacqueline Barton	Independent Director	6.4yrs	US$429.92k	0.0020% $ 1.5m
Eugene Schiff	Member of the Scientific Advisory Board	no data	データなし	データなし
Robert Schooley	Member of the Scientific Advisory Board	no data	データなし	データなし
Harish Manwani	Independent Director	6.1yrs	US$414.92k	0.0010% $ 768.1k
John Mellors	Member of the Scientific Advisory Board	no data	データなし	データなし
Francis Chisari	Member of the Scientific Advisory Board	no data	データなし	データなし
Paul Klotman	Member of the Scientific Advisory Board	no data	データなし	データなし
Kelly Kramer	Independent Director	7.8yrs	US$434.92k	0.00011% $ 82.0k
Joel Huff	Chairperson of Scientific Advisory Board	no data	データなし	データなし

6.1yrs

平均在職期間

71yo

平均年齢

経験豊富なボード: GISの取締役会は経験豊富であると考えられます ( 6.1年の平均在任期間)。

Gilead Sciences マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Gilead Sciences, Inc., Annual General Meeting, May 08, 2024

Gilead Sciences, Inc. Announces Retirement of Kevin E. Lofton from the Board, Effective May 8, 2024

Gilead Sciences, Inc. Appoints Ted Love to Board of Directors

Gilead Sciences, Inc. Appoints Ted Love to Board of Directors

Insufficient new directors

Recent updates

Gilead Sciences, Inc. Announces Data from the Phase 2b MYR204 Open-Label Study

Upcoming dividend of US$0.77 per share

Gilead Sciences, Inc. Announces Two-Year Interim Results from the Ongoing Assure Study of Investigational Seladelpar for the Treatment of Primary Biliary Cholangitis (Pbc), A Rare, Chronic Inflammatory Liver Disease

Gilead and Arcus Announces Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-Line Metastatic Colorectal Cancer

Gilead Sciences, Inc. Announces Detailed Results from the Phase 3 Evoke-01 Study

Gilead Sciences, Inc. Provides Update on Phase 3 Tropics-04 Study

Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

First quarter dividend of US$0.77 announced

Gilead Sciences, Inc. Announces U.S. Food and Drug Administration Approve Biktarvy® Label Update With Data for Pregnant Adults With HIV

First quarter 2024 earnings released: US$3.34 loss per share (vs US$0.81 profit in 1Q 2023)

Gilead Sciences, Inc. to Report Q1, 2024 Results on Apr 25, 2024

Gilead Sciences, Inc., Annual General Meeting, May 08, 2024

FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic Hbv Infection in Pediatric Patients as Young as Six

Gilead Sciences, Inc. (NasdaqGS:GILD) completed the acquisition of CymaBay Therapeutics, Inc. (NasdaqGS:CBAY).

Gilead Sciences, Inc. Announces Retirement of Kevin E. Lofton from the Board, Effective May 8, 2024

Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24

Upcoming dividend of US$0.77 per share

Gilead Sciences, Inc.'s Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health

Gilead Sciences, Inc. announced that it has received $210 million in funding from Abingworth LLP

Gilead Sciences, Inc. to Present Late-Breaking Data and Real-World Evidence Highlighting Innovative Antiviral Portfolio and Research Pipeline At CROI 2024

Gilead Sciences, Inc. (NasdaqGS:GILD) entered into an Agreement and Plan of Merger to acquire CymaBay Therapeutics, Inc. (NasdaqGS:CBAY) for $3.7 billion.

Fourth quarter dividend of US$0.77 announced

New minor risk - Financial position

Full year 2023 earnings released: EPS: US$4.54 (vs US$3.66 in FY 2022)

Gilead Sciences, Inc. Provides Earnings Guidance for the Full Year 2024

Gilead Sciences, Inc. Appoints Ted Love to Board of Directors

Gilead Sciences, Inc. Appoints Ted Love to Board of Directors

Gilead Sciences, Inc. to Report Q4, 2023 Results on Feb 06, 2024

Gilead Provides Update on Phase 3 Evoke-01 Study

Gilead Sciences, Inc. Announces U.S. FDA Approves Label Update for Kite’s Yescarta® CAR T-Cell Therapy to Include Overall Survival Data

Upcoming dividend of US$0.75 per share at 3.8% yield

New minor risk - Financial position

Gilead Sciences, Inc. Revises Earnings Guidance for the Year 2023

Third quarter 2023 earnings released: EPS: US$1.75 (vs US$1.43 in 3Q 2022)

Gilead Sciences, Inc. and Arcus Biosciences, Inc. Announces New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-Line Treatment for Upper GI Cancers

Gilead Sciences, Inc. to Present Late Breaking Data and Real World Evidence Highlighting Key Hepatitis Indications at The Liver Meeting®? 2023

Insufficient new directors

Gilead Sciences, Inc. Presents New Data Supporting Sunlenca®? (Lenacapavir) as an Important Treatment Option for Adults with Multi-Drug Resistant HIV

Gilead Sciences, Inc. Announces New Long-Term Real-World Data from BICSTaR Study Highlighting Safety and Efficacy Profile of Biktarvy as Treatment Regimen for Broad Range of People with HIV, Including Those with Prior Treatment History or Comorbidities

Gilead Sciences, Inc. Announces New Clinical Trial in Europe to Assess Lenacapavir for HIV Prevention as Part of Purpose Program

Gilead Demonstrates the Impact of Global Collaboration in Advancing Hiv Research and Health Equity At EACS 2023

Gilead Sciences, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Gilead Sciences, Inc. Announces CHMP of EMA Adopts Positive Opinion to Extend Use of Veklury (Remdesivir) to Treat COVID-19 in People with Hepatic Impairment

Kite, A Gilead Company Announces Car T-Cell Therapy Yescarta® Demonstrates High Response Rate and Durable Remission in ALYCANTE Study as Initial Treatment for Transplant Ineligible Patients with Relapsed/Refractory Large B-Cell Lymphoma

Gilead Sciences, Inc.'s Phase 2 EVOKE-02 Study of Trodelvy® (sacituzumab govitecan-hziy) in Combination With KEYTRUDA® (pembrolizumab) Demonstrates Promising Clinical Activity in First-Line Metastatic Non-Small Cell Lung Cancer

Upcoming dividend of US$0.75 per share at 4.0% yield

Gilead Sciences, Inc. Announces U.S. Food and Drug Administration Approval of Supplemental New Drug Application (sNDA) for the Use of Veklury (remdesivir)

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /34